EcoR1 Capital sells 64.05M shares (39% of holdings) in 3 trades for $6.9M at $0.11 blended avg; stock down -92.8% from 52-week high, -58.3% 30-day
EcoR1 Capital, a 10% owner of Adaptimmune Therapeutics, executed 3 separate sales totaling 64,052,538 shares for $6,890,235.51 between July 28–30, 2025, reducing its stake by 39.0% from 164,424,420 to 100,371,882 shares. The transactions occurred at a blended average of $0.11 per share while the current price stands at $0.10, and the stock has collapsed -92.8% from its 52-week high of $1.39 and -58.3% over the past 30 days. Against this backdrop of severe price deterioration and unprofitability ($-47,584,000 net income in the latest period despite +195.3% revenue growth), the substantial liquidation of the insider's position signals a major shift in the ownership structure. The insider's cross-ticker track record of 3 prior sells shows an average 30-day return of -10.7%, providing context that prior sales by this actor have not preceded price recoveries.